Current and Next Generation Therapeutics in Hepatology: An Issue of Clinics in Liver Disease: 29 (Clinics: Internal Medicine, 29). Questo articolo non è disponibile.Current and Next Generation Therapeutics in Hepatology: An Issue of Clinics in Liver Disease: 29 (Clinics: Internal Medicine, 29)

In this issue of Clinics in Liver Disease, guest editor Dr. Vinod K. Rustgi brings his considerable expertise to the topic of Current and Next Generation Therapeutics in Hepatology. Top experts in hepatology provide updates on the latest pharmaceuticals available as well as those in the pipeline for a wide range of liver diseases.

• Contains 11 relevant, practice-oriented topics including primer of CRISPR: gene therapy and molecular therapies; evolving treatments of cirrhosis; what is coming in the world of liver transplantation; weight loss drugs: current and future implications for liver disease; sensors and wearables in hepatology; and more
• Provides in-depth clinical reviews on current and next generation therapeutics in hepatology, offering actionable insights for clinical practice
• Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews

Dr. Vinod Rustgi is a Professor in Epidemiology in the School of Public Health and a Professor in Pathology and Lab Medicine. He previously served as Program Director for the Gastroenterology Fellowship until the 2022/2023 academic year and currently serves as Associate Program Director. He has extensive experience in hepatology spanning over 30 years and previously held the position of Medical Director of Liver Transplantation at the University of Pittsburgh's Starzl Transplant Institute. His research and clinical interests include outcomes research in nonalcoholic steatohepatitis (NASH), other liver diseases, and cost-effectiveness modeling. He has contributed to antiviral research associated with hepatitis C cure efforts and has served on the Governing Board of the American Association for the Study of Liver Diseases (AASLD).